325 related articles for article (PubMed ID: 35895074)
1. Endoscopic Postoperative Recurrence in Crohn's Disease After Curative Ileocecal Resection with Early Prophylaxis by Anti-TNF, Vedolizumab or Ustekinumab: A Real-World Multicentre European Study.
Yanai H; Kagramanova A; Knyazev O; Sabino J; Haenen S; Mantzaris GJ; Mountaki K; Armuzzi A; Pugliese D; Furfaro F; Fiorino G; Drobne D; Kurent T; Yassin S; Maharshak N; Castiglione F; de Sire R; Nardone OM; Farkas K; Molnar T; Krznaric Z; Brinar M; Chashkova E; Livne Margolin M; Kopylov U; Bezzio C; Bar-Gil Shitrit A; Lukas M; Chaparro M; Truyens M; Nancey S; Lobaton T; Gisbert JP; Saibeni S; Bacsúr P; Bossuyt P; Schulberg J; Hoentjen F; Viganò C; Palermo A; Torres J; Revés J; Karmiris K; Velegraki M; Savarino E; Markopoulos P; Tsironi E; Ellul P; Calviño Suárez C; Weisshof R; Ben-Hur D; Naftali T; Eriksson C; Koutroubakis IE; Foteinogiannopoulou K; Limdi JK; Liu E; Surís G; Calabrese E; Zorzi F; Filip R; Ribaldone DG; Snir Y; Goren I; Banai-Eran H; Broytman Y; Amir Barak H; Avni-Biron I; Ollech JE; Dotan I; Aharoni Golan M
J Crohns Colitis; 2022 Dec; 16(12):1882-1892. PubMed ID: 35895074
[TBL] [Abstract][Full Text] [Related]
2. Early Initiation of Antitumor Necrosis Factor Therapy Reduces Postoperative Recurrence of Crohn's Disease Following Ileocecal Resection.
Axelrad JE; Li T; Bachour SP; Nakamura TI; Shah R; Sachs MC; Chang S; Hudesman DP; Holubar SD; Lightner AL; Barnes EL; Cohen BL; Rieder F; Esen E; Remzi F; Regueiro M; Click B
Inflamm Bowel Dis; 2023 Jun; 29(6):888-897. PubMed ID: 35905032
[TBL] [Abstract][Full Text] [Related]
3. Real-world clinical outcomes and healthcare costs in patients with Crohn's disease treated with vedolizumab versus ustekinumab in the United States.
Chiorean M; Jiang J; Candela N; Chen G; Romdhani H; Latremouille-Viau D; Shi S; Bungay R; Guerin A; Fan T
Curr Med Res Opin; 2024 May; 40(5):877-885. PubMed ID: 38586979
[TBL] [Abstract][Full Text] [Related]
4. Comparative Effectiveness of Biologic Therapies in Preventing Penetrating Complications in Patients With Crohn's Disease.
McCurdy JD; Stwalley D; Olsen MA; Deepak P
Clin Gastroenterol Hepatol; 2024 Feb; 22(2):377-385.e5. PubMed ID: 37673348
[TBL] [Abstract][Full Text] [Related]
5. Postoperative Safety Profile of Minimally Invasive Ileocolonic Resections for Crohn's Disease in the Era of Biologic Therapy.
Abd El Aziz MA; Abdalla S; Calini G; Saeed H; Stocchi L; Merchea A; Colibaseanu DT; Shawki S; Larson DW
J Crohns Colitis; 2022 Aug; 16(7):1079-1088. PubMed ID: 35045164
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of ustekinumab, vedolizumab, or a second anti-TNF agent after the failure of a first anti-TNF agent in patients with Crohn's disease: a multicentre retrospective study.
Rayer C; Nachury M; Bourreille A; Roblin X; Peyrin-Biroulet L; Viennot S; Flamant M; Laharie D; Caron B; Dewitte M; Siproudhis L; Fumery M; Bouguen G
BMC Gastroenterol; 2022 Dec; 22(1):498. PubMed ID: 36457080
[TBL] [Abstract][Full Text] [Related]
7. Therapeutic sequencing in inflammatory bowel disease: Determining the optimal position of vedolizumab for long-term Crohn's disease control using real-world evidence.
Louis E; Litkiewicz M; Agboton C; Armuzzi A
United European Gastroenterol J; 2024 Jun; 12(5):574-584. PubMed ID: 38717013
[TBL] [Abstract][Full Text] [Related]
8. The effectiveness of ustekinumab and vedolizumab as third-line biologic therapy in patients with Crohn's disease.
Macaluso FS; Grova M; Saladino M; Cappello M; Demarzo MG; Privitera AC; Giangreco E; Garufi S; Renna S; Casà A; Ventimiglia M; Fries W; Orlando A;
Dig Liver Dis; 2023 Apr; 55(4):471-477. PubMed ID: 36127230
[TBL] [Abstract][Full Text] [Related]
9. Long-term effectiveness of ustekinumab comparable to antitumor necrosis factor agents in patients with Crohn's disease.
Shiga H; Tarasawa K; Moroi R; Makuuchi M; Takahashi T; Shimoyama Y; Kuroha M; Kakuta Y; Fushimi K; Fujimori K; Kinouchi Y; Masamune A
J Gastroenterol Hepatol; 2022 Nov; 37(11):2105-2112. PubMed ID: 36059265
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of swapping to ustekinumab after vedolizumab failure in patients with multi-refractory Crohn's disease.
Melotti L; Dussias NK; Salice M; Calabrese C; Baldoni M; Scaioli E; Belluzzi A; Mazzotta E; Gionchetti P; Rizzello F
Dig Liver Dis; 2023 Feb; 55(2):230-234. PubMed ID: 35879185
[TBL] [Abstract][Full Text] [Related]
11. Real-world Comparative Effectiveness of Ustekinumab vs Anti-TNF in Crohn's Disease With Propensity Score Adjustment: Induction Phase Results From the Prospective, Observational RUN-CD Study.
Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Mohl W; Teich N; Hoffstadt M; Schweitzer A; von der Ohe M; Gauss A; Atreya R; Krause T; Blumenstein I; Hartmann P; Schreiber S
Inflamm Bowel Dis; 2023 Nov; 29(11):1741-1750. PubMed ID: 36633301
[TBL] [Abstract][Full Text] [Related]
12. Prior Immunogenicity to Anti-TNF Biologics Is Not Associated with Increased Anti-drug Antibodies to Vedolizumab or Ustekinumab.
Costable NJ; Borman ZA; Ji J; Dubinsky MC; Ungaro RC
Dig Dis Sci; 2022 Jun; 67(6):2480-2484. PubMed ID: 34021427
[TBL] [Abstract][Full Text] [Related]
13. Comparative Effectiveness of Ustekinumab and Anti-TNF Agent as First-Line Biological Therapy in Luminal Crohn's Disease: A Retrospective Study From 2 Referral Centers.
Rivière P; Kanters C; Pellet G; Ni A; Hupé M; Aboulhamid N; Poullenot F; Bitton A; Zerbib F; Lakatos PL; Afif W; Laharie D; Bessissow T
Inflamm Bowel Dis; 2023 Jun; 29(6):923-931. PubMed ID: 35917111
[TBL] [Abstract][Full Text] [Related]
14. Anti-TNF Agents and New Biological Agents (Vedolizumab and Ustekinumab) in the Prevention and Treatment of Postoperative Recurrence After Surgery in Crohn's Disease.
Gisbert JP; Chaparro M
Drugs; 2023 Sep; 83(13):1179-1205. PubMed ID: 37505446
[TBL] [Abstract][Full Text] [Related]
15. Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry.
Chugh R; Long MD; Jiang Y; Weaver KN; Beaulieu DB; Scherl EJ; Mahadevan U
Am J Gastroenterol; 2024 Mar; 119(3):468-476. PubMed ID: 37796648
[TBL] [Abstract][Full Text] [Related]
16. Comparative Persistence of Non-tumor Necrosis Factor (TNF) vs. TNF Antagonists for Post-operative Prophylaxis in Crohn's Disease (CD).
Gu P; Dube S; Lee Y; Yang S; Li D; Haritunians T; Vasiliauskas E; Bonthala N; Syal G; Yarur A; Ziring D; Targan S; Rabizadeh S; Melmed GY; Fleshner P; McGovern DPB
Dig Dis Sci; 2024 Jan; 69(1):235-245. PubMed ID: 38015321
[TBL] [Abstract][Full Text] [Related]
17. Biologic Therapy for Inflammatory Bowel Disease: Real-World Comparative Effectiveness and Impact of Drug Sequencing in 13 222 Patients within the UK IBD BioResource.
Kapizioni C; Desoki R; Lam D; Balendran K; Al-Sulais E; Subramanian S; Rimmer JE; De La Revilla Negro J; Pavey H; Pele L; Brooks J; Moran GW; Irving PM; Limdi JK; Lamb CA; ; Parkes M; Raine T
J Crohns Colitis; 2024 Jun; 18(6):790-800. PubMed ID: 38041850
[TBL] [Abstract][Full Text] [Related]
18. Systematic Review and Meta-Analysis: Association between Preoperative Ustekinumab and Surgical Complications in Crohn's Disease Patients.
Li L; Jiang K; Lou D; Zhang M; Shi Y; Shen J; Fu X
Eur Surg Res; 2023; 64(4):412-421. PubMed ID: 37598662
[TBL] [Abstract][Full Text] [Related]
19. Comparative Study of the Effectiveness of Vedolizumab Versus Ustekinumab After Anti-TNF Failure in Crohn's Disease (Versus-CD): Data from the ENEIDA Registry.
García MJ; Rivero M; Fernández-Clotet A; de Francisco R; Sicilia B; Mesonero F; de Castro ML; Casanova MJ; Bertoletti F; García-Alonso FJ; López-García A; Vicente R; Calvet X; Barreiro-de Acosta M; Ferrer Rosique J; Varela Trastoy P; Nuñez A; Ricart E; Riestra S; Arias García L; Rodríguez M; Arranz L; Pajares R; Mena R; Calafat M; Camo P; Bermejo F; Ponferrada Á; Madrigal RE; Llaó J; Sesé E; Sánchez E; Pineda Mariño JR; González Muñoza C; Carbajo López AY; Julián AB; Villoria Ferrer A; Baston-Rey I; Jara L; Almela P; Codesido L; de la Maza S; Leal C; Caballol B; Pérez-Martínez I; Vinuesa Campo R; Crespo J; Domènech E; Chaparro M; Gisbert JP
J Crohns Colitis; 2024 Jan; 18(1):65-74. PubMed ID: 37522878
[TBL] [Abstract][Full Text] [Related]
20. Vedolizumab more likely to be discontinued than ustekinumab in anti-TNF-experienced patients with fistulizing Crohn's disease.
Newman KL; Johnson LA; Stidham RW; Higgins PDR
Therap Adv Gastroenterol; 2023; 16():17562848221148254. PubMed ID: 36895282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
